Peptic Ulcer Drugs Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, 2020-2030

Proton Pump Inhibitors is the fastest growing segment, North America is the largest market globally

The Global Peptic Ulcer Drugs Market will grow from USD 3.54 Billion in 2024 to USD 4.31 Billion by 2030 at a 3.32% CAGR. Peptic ulcer drugs comprise pharmaceutical agents formulated to treat open sores that develop on the lining of the stomach, small intestine, or esophagus, primarily resulting from *Helicobacter pylori* infection or prolonged use of nonsteroidal anti-inflammatory drugs. The market's expansion is fundamentally driven by the escalating global prevalence of *H. pylori* infections and the extensive use of NSAIDs.

Key Market Drivers

The global peptic ulcer drugs market is significantly driven by the persistent high incidence of *Helicobacter pylori* infection. This bacterium is a primary etiological factor for peptic ulcer disease, necessitating targeted antimicrobial and acid-suppressing therapies for successful eradication and healing. The widespread nature of this infection ensures a continuous and substantial patient pool requiring diagnostic procedures and a comprehensive array of pharmaceutical interventions.

Key Market Challenges

A significant impediment to the sustained expansion of the global peptic ulcer drugs market is the escalating antibiotic resistance encountered in *Helicobacter pylori* eradication regimens. This challenge directly undermines the effectiveness of established first-line therapies, leading to suboptimal patient outcomes. When bacteria develop resistance to antibiotics, the standard treatment protocols become less efficacious, often necessitating longer treatment durations, the use of more complex drug combinations, or the administration of higher doses, all of which increase treatment burden and healthcare costs.

Key Market Trends

The global peptic ulcer drugs market is experiencing a significant shift towards Potassium-Competitive Acid Blockers (P-CABs), marking an advancement in acid suppression therapy. P-CABs offer benefits such as rapid onset and consistent acid suppression, addressing limitations of traditional proton pump inhibitors. Their integration into treatment protocols is expanding, especially for patients unresponsive to conventional therapies. According to the American Gastroenterological Association's Clinical Practice Update, published in January 2025, P-CABs are recommended in place of proton pump inhibitors for most patients with *Helicobacter pylori* and other conditions where initial therapies have failed.

Key Market Players Profiled:

• Daewoong Pharmaceutical Co., Ltd
• Takeda Pharmaceutical Co., Ltd.
• Pfizer Inc.
• AstraZeneca plc.
• RedHill Biopharma Ltd.
• Zydus Lifesciences Limited
• ANI Pharmaceuticals, Inc. (Novitium Pharma LLC.)
• Boehringer Ingelheim International GmbH
• Eisai Co. Ltd.
• Yuhan Corporation

Report Scope:

In this report, the Global Peptic Ulcer Drugs Market has been segmented into the following categories:

By Product Type:

• Proton Pump Inhibitors
• Potassium-Competitive Acid Blocker (P-CAB)
• Antacids
• H2- Antagonist
• Antibiotics
• Ulcer Protective

By Disease Indication:

• Gastitis
• Gastric Ulcer
• Duodenal Ulcer
• Gastroesophageal Reflux Disease (GERD)

By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• E-Commerce

By Region:

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Peptic Ulcer Drugs Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report:

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.